Alterity Therapeutics (ATHE)

• Market cap: $57.5M
• 1 day: -2.76%
• 5 days: -10.7%
• 1 month: 3.59%
• 3 months: -31.09%
• 6 months: -38.68%
• Year to date: 0.32%
• 1 year: -30.63%
• 5 years: -81.57%
• 10 years: -90.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

Employees: 9